Management of N2/IIIA Non-Small-Cell Lung Cancer

Management of N2/IIIA Non-Small-Cell Lung Cancer PDF

Author: Mithran S. Sukumar

Publisher:

Published: 2008

Total Pages: 0

ISBN-13: 9781416063629

DOWNLOAD EBOOK →

Preface / Mithran S. Sukumar -- Defining N2 Disease in Non-Small Cell Lung Cancer / Edmund S. Kassis, Ara A. Vaporciyan -- Detection of Occult N2 Disease with Molecular Techniques / Loretta Erhunmwunsee, Thomas A. D'Amico -- Radiographic Staging of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer Patients / Shawn S. Groth, Bryan A. Whitson, Michael A. Maddaus -- Minimally Invasive Staging of N2 Disease : Endobronchial Ultrasound/Transesophageal Endoscopic Ultrasound, Mediastinoscopy, and Thoracoscopy / Paul Schipper, Matt Schoolfield -- Intraoperative Staging and Surgical Management of Stage IIIA/N2 Non-Small Cell Lung Cancer / Igor Brichkov, Steven M. Keller -- Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer with N2 Disease / Shilpen Patel, Rachel E. Sanborn, Charles R. Thomas -- Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer with Mediastinal Lymph Node Involvement / Brandon H. Tieu, Rachel E. Sanborn, Charles R. Thomas -- Restaging After Neo-Adjuvant Chemoradiotherapy for N2 Non-Small Cell Lung Cancer / Robert J. Cerfolio, Ayesha S. Bryant -- Adjuvant Therapy for Non-Small Cell Lung Cancer with Mediastinal Nodal Involvement / Rachel E. Sanborn, Brian E. Lally -- Management Algorithms for Stage IIIA Non-Small Cell Lung Cancer with N2 Node Involvement / Frank Detterbeck, Mithran S. Sukumar.

Diagnosis and Treatment of Lung Cancer

Diagnosis and Treatment of Lung Cancer PDF

Author: Frank C. Detterbeck

Publisher: Saunders

Published: 2001

Total Pages: 512

ISBN-13:

DOWNLOAD EBOOK →

Access comprehensive, multidisciplinary guidance on the diagnosis and treatment of lung cancer! This new resource addresses the full range of clinical issues in diagnosis, staging, and treatment, as well as the latest scientific data and evidence-based guidelines. A user-friendlyorganization provides quick reference to data summaries, as well as more comprehensive and detailed information for readers who wish to explore topics in depth. Features contributions by authors from many different disciplines, to ensure a balanced approach. Addresses the clinical issues seen in practice, with the inclusion of basic science research topics that are likely to be put into clinical practice soon. Integrates evidence-based medicine throughout. Assesses the strength of all available dataenabling readers to weigh different arguments and make decisions based on medical issues, values, and the availability and efficacy of interventionsusing a data rating system. Addresses difficult, but clinically relevant issues for which limited data is available. Enables readers to quickly reference findings and data in data summary statements and summary tables.

Controversies in the Local Management of Lung Cancer

Controversies in the Local Management of Lung Cancer PDF

Author: John M. Varlotto

Publisher: Frontiers Media SA

Published: 2018-08-30

Total Pages: 92

ISBN-13: 2889455610

DOWNLOAD EBOOK →

This special edition of Frontiers in Oncology reviews the current efficacy and limitations of surgical and radiotherapeutic management of lung cancer and provides insight into how local management options may change in the future.

Basic Radiation Oncology

Basic Radiation Oncology PDF

Author: Murat Beyzadeoglu

Publisher: Springer Nature

Published: 2022-01-01

Total Pages: 541

ISBN-13: 3030873080

DOWNLOAD EBOOK →

This practical, up-to-date, bedside-oriented radiation oncology book encompasses the essential aspects of the subject with coverage on radiation physics, radiobiology, and clinical radiation oncology. The first two sections examine concepts that are crucial in radiation physics and radiobiology. The third section describes radiation treatment regimens appropriate for the main cancer sites and tumor types.

Lung Cancer

Lung Cancer PDF

Author: Kemp H. Kernstine

Publisher: Demos Medical Publishing

Published: 2011

Total Pages: 724

ISBN-13: 1936287064

DOWNLOAD EBOOK →

Over the course of the last decade, the treatment of lung cancer has evolved quite rapidly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of lung cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment. Written by a multidisciplinary team of authors representing a range of disciplines, is a valuable resource for physicians, fellows, nurses, physician assistants, physical therapists, and all health care providers involved in the treatment of lung cancer

Prognostic Value of Lymph Node Ratio After Induction Therapy in Stage IIIA/N2 Non-small Cell Lung Cancer

Prognostic Value of Lymph Node Ratio After Induction Therapy in Stage IIIA/N2 Non-small Cell Lung Cancer PDF

Author: Benedikt Christoph Haager

Publisher:

Published: 2018

Total Pages: 0

ISBN-13:

DOWNLOAD EBOOK →

Abstract: Background: The optimal treatment modalities for patients with stage IIIA N2 non-small cell lung cancer (NSCLC) are still a matter of debate. To provide best outcome and to avoid unnecessary treatment patient selection for surgical therapy is crucial. In addition to mediastinal downstaging the lymph node ratio (LNR) has been suggested as a prognosticator in this patient group. Methods: We retrospectively reviewed clinical and histopathologic data of 78 patients with stage IIIA N2 NSCLC, who underwent induction therapy with two cycles of platinum-based chemotherapy for intended surgery at our clinic between 2009 and 2016. To evaluate the prognostic value of the LNR the cut off was set at 0.33 as reported in prior literature. Results: The median follow-up time was 30.1 months. In multivariate analysis mediastinal down staging was associated with a longer overall survival (OS): 52.2 (range, 5.9-89.7) months for ypN0 versus 24.6 (4.4-84.2) months for ypN1/2 (HR, 2.76; 95% CI, 1.07-7.1, P=0.0348). LNR ≤0.33 was linked to a better OS of 39.3 (range, 5.9-89.7) months compared to 14.7 (range, 4.4-66.2) months for a LNR >0.33 in univariate analysis (P=0.037). In multivariate analysis a statistical trend could be observed (HR, 2.82; 95% CI, 0.98-8.14, P=0.1). In patients with persistent lymph node involvement the LNR could also identify a subgroup of patients with a favorable prognosis (30.1 vs. 14.7 months, P=0.145). Conclusions: Mediastinal downstaging remains the best prognosticator in stage IIIA N2 NSCLC after induction therapy. However, using the LNR in patients with persistent mediastinal lymph node metastasis a subgroup with a favorable prognosis could be identified. The LNR could aid in finding the best treatment modalities for these patients. Keywords: Mediastinal lymph node metastasis; mediastinal downstaging; advanced lung cancer

Lanterna Rally - Theme by Grace Themes